Dupilumab-induced psoriasiform dermatitis in two pediatric cardiac transplant patients.
Trevor LockardSarah A MullenErica B LeeHana NieburNicole HarterPublished in: Pediatric dermatology (2023)
Dupilumab is an interleukin-4 receptor antagonist important in the treatment of refractory atopic dermatitis (AD), particularly among pediatric patients. Two boys with a history of AD and cardiac transplant who developed psoriasiform dermatitis in response to dupilumab therapy are reported. These patients paradoxically developed an immune-mediated adverse drug reaction despite taking systemic immunosuppressive agents. While the literature suggests possible pathomechanisms for psoriasiform dermatitis despite immunosuppression, further research is necessary to better characterize this unique and unexpected phenomenon.
Keyphrases
- atopic dermatitis
- end stage renal disease
- chronic kidney disease
- ejection fraction
- newly diagnosed
- adverse drug
- prognostic factors
- peritoneal dialysis
- stem cells
- left ventricular
- heart failure
- patient reported outcomes
- drug induced
- oxidative stress
- endothelial cells
- combination therapy
- cell therapy
- electron transfer